デフォルト表紙
市場調査レポート
商品コード
1769601

医薬品中間体CDMOの世界市場:用途別、中間体タイプ別、医薬品タイプ別、地域別 - 2035年までの予測分析

Global Pharmaceutical Intermediate CDMO Market Research Report by Application, by Type of Intermediate, by Drug Type, and by Region Forecast Analysis till 2035


出版日
ページ情報
英文 146 Pages
納期
即納可能 即納可能とは
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.47円
医薬品中間体CDMOの世界市場:用途別、中間体タイプ別、医薬品タイプ別、地域別 - 2035年までの予測分析
出版日: 2025年07月07日
発行: Market Research Future
ページ情報: 英文 146 Pages
納期: 即納可能 即納可能とは
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の医薬品中間体CDMOの市場規模は、2024年に1,617億9,890万米ドルとなりました。同市場は、2024年から2035年にかけて7.4%のCAGRで拡大し、3,467億4,430万米ドルに達すると予測されています。

世界の医薬品中間体CDMO市場は、さまざまな要因によって急速に拡大しています。製薬企業によるアウトソーシングは、効率性の向上と業務負担の軽減を目的として増加傾向にあります。特に中低所得国では、ジェネリック医薬品やバイオシミラーのニーズが高まっており、これが大きな成長要因となっています。さらに、中間体合成技術の進歩や新薬製剤の複雑な性質が、企業を専門的なCDMO支援へと向かわせています。新興国におけるヘルスケア・インフラの成長も市場情勢を高めています。

その反面、厳しい規制遵守要件や長い承認スケジュールが、しばしば進展の妨げとなっています。高い資本・運営費用、知的財産権関連のリスク、継続的なサプライチェーンの混乱が、顕著な障壁となっています。先端化学の専門家不足も課題のひとつです。このような問題にもかかわらず、バイオテクノロジー企業との戦略的提携や、オーダーメイドの患者特異的な医薬品ソリューションに対する需要の高まりを通じて、この市場には有望な機会が残されています。

産業区分

用途別では、世界市場はがん、心血管疾患、中枢神経系および神経疾患、感染症に分類されます。

医薬品タイプ別では、世界の医薬品中間体CDMO市場はジェネリック医薬品とブランド医薬品で構成されます。

世界の医薬品中間体CDMO市場は中間体タイプによって分類され、原薬(API)、生物製剤中間体、賦形剤・添加剤、ヌクレオチド中間体が含まれます。

地域別では、世界の医薬品中間体CDMO市場は北米、欧州、南米、中東・アフリカ、アジア太平洋に分けられます。

地域別分析

北米の医薬品中間体CDMO市場は最大かつ最も洗練された市場であり、ハイテクインフラ、大規模な研究開発投資、FDAによる品質規制により米国がリードしています。カナダのバイオ医薬品産業の成長は、この地域の強さをさらに支えています。

欧州は、規制遵守、複雑な合成における革新性、循環経済の原則に沿った持続可能な生産方式を重視し、国内の有力企業と世界企業の両方に対応しています。

中国とインドを筆頭とするアジア太平洋地域が最も急速に成長しています。コスト効率の高い製造、大規模施設、統合されたサプライチェーンにより、競争力のある中間体の生産が可能となっています。

ラテンアメリカは、国によって多様な規制の枠組みに直面しながらも、地域協力を通じて統一基準を目指しています。競争力のある人件費と米国への近さが有利だが、インフラ制約が成長をやや妨げています。

中東・アフリカでは、CDMOは主にジェネリック医薬品や必須医薬品の中間体を製造することで、地元や近隣の市場に貢献しています。アジアと欧州の中間に位置するこの地域は、医薬品ロジスティクスと中間体供給における潜在的なハブとして位置づけられています。世界・サプライチェーンが発展するにつれて、大陸間の製造努力の橋渡し役としてMEAの役割はより顕著になる可能性があります。

主要企業

Thermo Fisher Scientific、Raghava Life Sciences Pvt LTD.、Cambrex Corporation、Actylis、Chiracon GmbH、Codexis, Inc.、Arkema S.A.、Lonza Group AG、Catalent, Inc.、Zhejiang Jiuzhou Pharmaceutical Co Ltd.が世界の医薬品中間体CDMO市場の主要な競合企業です。

当レポートでは、世界の医薬品中間体CDMO市場について調査し、市場の概要とともに、用途別、中間体タイプ別、医薬品タイプ別、地域別の動向、および市場に参入する企業のプロファイルなどをまとめています。

目次

第1章 エグゼクティブサマリー

第2章 市場イントロダクション

第3章 調査手法

第4章 市場力学

  • イントロダクション
  • 促進要因
    • 製薬会社のアウトソーシングの増加
    • ジェネリック医薬品とバイオシミラーの需要増加
    • 中間体合成における技術の進歩
    • 薬物分子の複雑性の増大
    • 新興市場への進出
  • 抑制要因
    • 厳格な規制遵守と複雑な承認プロセス
    • 高い運用コストと設備投資コスト
    • 財産(IP)リスクと機密性に関する懸念
    • サプライチェーンの混乱と原材料不足
    • 先端技術とニッチ化学に関する専門知識が限られている
  • 機会
    • バイオテクノロジー企業との戦略的パートナーシップ
    • 個別化医療ソリューションに焦点を当てる
  • COVIDの影響分析-

第5章 市場要因分析

  • サプライチェーン分析
    • 原材料調達
    • 調査、開発、プロセス最適化
    • 製造と品質管理
    • 包装、保管、物流、配送、顧客への配送
  • ポーターのファイブフォースモデル

第6章 世界の医薬品中間体CDMO市場(中間体タイプ別)

  • イントロダクション
  • 原薬(API)
  • 賦形剤および添加物

第7章 世界の医薬品中間体CDMO市場(医薬品タイプ別)

  • イントロダクション
  • ジェネリック医薬品
  • ブランド医薬品

第8章 世界の医薬品中間体CDMO市場(用途別)

  • イントロダクション
  • 腫瘍学
  • 心血管疾患
  • 中枢神経系および神経疾患
  • 感染症
  • その他

第9章 世界の医薬品中間体CDMO市場(地域別)

  • 世界
  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • ロシア
    • その他
  • アジア太平洋
    • 中国
    • 韓国
    • インド
    • 日本
    • インドネシア
    • マレーシア
    • タイ
    • その他
  • 南米
    • メキシコ
    • ブラジル
    • アルゼンチン
    • その他
  • 中東・アフリカ
    • GCC諸国
    • 南アフリカ
    • その他

第10章 競合情勢

  • イントロダクション
  • 市場シェア分析、2024年
  • 競合ダッシュボード

第11章 企業プロファイル

  • RAGHAVA LIFE SCIENCES PVT LTD
  • ACTYLIS
  • CHIRACON GMBH
  • CODEXIS, INC.
  • ARKEMA S.A.
  • LONZA GROUP AG
  • THERMO FISHER SCIENTIFIC(PATHEON)
  • CAMBREX CORPORATION
  • CATALENT, INC.
  • ZHEJIANG JIUZHOU PHARMACEUTICAL CO LTD
図表

LIST OF TABLES

  • TABLE 1 GLOBAL PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION)
  • TABLE 2 GLOBAL PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION)
  • TABLE 3 GLOBAL PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 4 GLOBAL PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY REGION, 2019-2035 (USD MILLION)
  • TABLE 5 NORTH AMERICA: PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY COUNTRY, 2019-2035 (USD MILLION)
  • TABLE 6 NORTH AMERICA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION)
  • TABLE 7 NORTH AMERICA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION)
  • TABLE 8 NORTH AMERICA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 9 USA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION)
  • TABLE 10 USA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION)
  • TABLE 11 USA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 12 CANADA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION)
  • TABLE 13 CANADA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION)
  • TABLE 14 CANADA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 15 EUROPE: PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY COUNTRY, 2019-2032 (USD MILLION)
  • TABLE 16 EUROPE PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION)
  • TABLE 17 EUROPE PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION)
  • TABLE 18 EUROPE PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 19 UK PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION)
  • TABLE 20 UK PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION)
  • TABLE 21 UK PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 22 GERMANY PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION)
  • TABLE 23 GERMANY PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION)
  • TABLE 24 GERMANY PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 25 FRANCE PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION)
  • TABLE 26 FRANCE PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION)
  • TABLE 27 FRANCE PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 28 ITALY PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION)
  • TABLE 29 ITALY PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION)
  • TABLE 30 ITALY PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 31 SPAIN PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION)
  • TABLE 32 SPAIN PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION)
  • TABLE 33 SPAIN PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 34 RUSSIA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION)
  • TABLE 35 RUSSIA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION)
  • TABLE 36 RUSSIA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 37 REST OF EUROPE PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION)
  • TABLE 38 REST OF EUROPE PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION)
  • TABLE 39 REST OF EUROPE PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 40 ASIA PACIFIC: PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY COUNTRY, 2019-2035 (USD MILLION)
  • TABLE 41 ASIA PACIFIC PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION)
  • TABLE 42 ASIA PACIFIC PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION)
  • TABLE 43 ASIA PACIFIC PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 44 CHINA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION)
  • TABLE 45 CHINA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION)
  • TABLE 46 CHINA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 47 SOUTH KOREA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION)
  • TABLE 48 SOUTH KOREA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION)
  • TABLE 49 SOUTH KOREA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 50 INDIA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION)
  • TABLE 51 INDIA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION)
  • TABLE 52 INDIA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 53 JAPAN PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION)
  • TABLE 54 JAPAN PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION)
  • TABLE 55 JAPAN PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 56 INDONESIA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION)
  • TABLE 57 INDONESIA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION)
  • TABLE 58 INDONESIA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 59 MALAYSIA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION)
  • TABLE 60 MALAYSIA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION)
  • TABLE 61 MALAYSIA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 62 THAILAND PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION)
  • TABLE 63 THAILAND PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION)
  • TABLE 64 THAILAND PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 65 REST OF APAC PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION)
  • TABLE 66 REST OF APAC PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION)
  • TABLE 67 REST OF APAC PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 68 SOUTH AMERICA: PHARMACEUTICAL INTERMEDIATE CDMO, BY COUNTRY, 2019-2035 (USD MILLION)
  • TABLE 69 SOUTH AMERICA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION)
  • TABLE 70 SOUTH AMERICA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION)
  • TABLE 71 SOUTH AMERICA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 72 MEXICO PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION)
  • TABLE 73 MEXICO PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION)
  • TABLE 74 MEXICO PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 75 BRAZIL PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION)
  • TABLE 76 BRAZIL PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION)
  • TABLE 77 BRAZIL PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 78 ARGENTINA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION)
  • TABLE 79 ARGENTINA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION)
  • TABLE 80 ARGENTINA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 81 REST OF SOUTH AMERICA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION)
  • TABLE 82 REST OF SOUTH AMERICA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION)
  • TABLE 83 REST OF SOUTH AMERICA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 84 MIDDEL EAST AND AFRICA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY COUNTRY, 2019-2035 (USD MILLION)
  • TABLE 85 MIDDLE EAST & AFRICA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION)
  • TABLE 86 MIDDLE EAST & AFRICA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION)
  • TABLE 87 MIDDLE EAST & AFRICA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 88 GCC COUNTRIES PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION)
  • TABLE 89 GCC COUNTRIES PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION)
  • TABLE 90 GCC COUNTRIES PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 91 SOUTH AFRICA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION)
  • TABLE 92 SOUTH AFRICA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION)
  • TABLE 93 SOUTH AFRICA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 94 REST OF MEA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION)
  • TABLE 95 REST OF MEA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION)
  • TABLE 96 REST OF MEA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 97 RAGHAVA LIFE SCIENCES PVT LTD: PRODUCT OFFERED
  • TABLE 98 ACTYLIS: PRODUCT OFFERED
  • TABLE 99 ACTYLIS: PRODUCT OFFERED
  • TABLE 100 CHIRACON GMBH: PRODUCT OFFERED
  • TABLE 101 CODEXIS, INC.: PRODUCT OFFERED
  • TABLE 102 CODEXIS, INC.: PRODUCT OFFERED
  • TABLE 103 ARKEMA S.A.: PRODUCT OFFERED
  • TABLE 104 LONZA GROUP AG: PRODUCT OFFERED
  • TABLE 105 LONZA GROUP AG: PRODUCT OFFERED
  • TABLE 106 THERMO FISHER SCIENTIFIC (PATHEON): PRODUCT OFFERED
  • TABLE 107 THERMO FISHER SCIENTIFIC (PATHEON): PRODUCT OFFERED
  • TABLE 108 CAMBREX CORPORATION: PRODUCT OFFERED
  • TABLE 109 CAMBREX CORPORATION: PRODUCT OFFERED
  • TABLE 110 CATALENT, INC.: PRODUCT OFFERED
  • TABLE 111 CATALENT, INC.: PRODUCT OFFERED
  • TABLE 112 ZHEJIANG JIUZHOU PHARMACEUTICAL CO LTD: PRODUCT OFFERED
  • TABLE 113 ZHEJIANG JIUZHOU PHARMACEUTICAL CO LTD: PRODUCT OFFERED

LIST OF FIGURES

  • FIGURE 1 GLOBAL PHARMACEUTICAL INTERMEDIATE CDMO MARKETSEGMENT
  • FIGURE 2 DRIVER IMPACT ANALYSIS (2018-2035)
  • FIGURE 3 RESTRAINT IMPACT ANALYSIS (2018-2035)
  • FIGURE 4 SUPPLY CHAIN ANALYSIS
  • FIGURE 5 PORTER'S FIVE FORCES MODEL: GLOBAL PHARMACEUTICAL INTERMEDIATE CDMO MARKET
  • FIGURE 6 GLOBAL PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2024 (% SHARE)
  • FIGURE 7 GLOBAL PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2024 (% SHARE)
  • FIGURE 8 GLOBAL PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2024 (% SHARE)
  • FIGURE 9 GLOBAL PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY REGION, 2024 (% SHARE)
  • FIGURE 10 NORTH AMERICAN MARKET: SWOT ANALYSIS
  • FIGURE 11 NORTH AMERICA: PHARMACEUTICAL INTERMEDIATE CDMO MARKETSHARE, BY COUNTRY, 2024 (% SHARE)
  • FIGURE 12 NORTH AMERICA: PHARMACEUTICAL INTERMEDIATE CDMO MARKETSHARE, BY TYPE, 2024 (% SHARE)
  • FIGURE 13 NORTH AMERICA: PHARMACEUTICAL INTERMEDIATE CDMO MARKETSHARE, BY FREQUENCY, 2024 (% SHARE)
  • FIGURE 14 NORTH AMERICA: PHARMACEUTICAL INTERMEDIATE CDMO MARKETSHARE, BY APPLICATION, 2024 (% SHARE)
  • FIGURE 15 EUROPE MARKET: SWOT ANALYSIS
  • FIGURE 16 EUROPE: PHARMACEUTICAL INTERMEDIATE CDMO MARKETSHARE, BY COUNTRY, 2024 (% SHARE)
  • FIGURE 17 EUROPE: PHARMACEUTICAL INTERMEDIATE CDMO MARKETSHARE, BY TYPE, 2024 (% SHARE)
  • FIGURE 18 EUROPE: PHARMACEUTICAL INTERMEDIATE CDMO MARKETSHARE, BY FREQUENCY, 2024 (% SHARE)
  • FIGURE 19 EUROPE: PHARMACEUTICAL INTERMEDIATE CDMO MARKETSHARE, BY APPLICATION, 2024 (% SHARE)
  • FIGURE 20 ASIA PACIFIC MARKET: SWOT ANALYSIS
  • FIGURE 21 ASIA PACIFIC: PHARMACEUTICAL INTERMEDIATE CDMO MARKETSHARE, BY COUNTRY, 2024 (% SHARE)
  • FIGURE 22 ASIA PACIFIC: PHARMACEUTICAL INTERMEDIATE CDMO MARKETSHARE, BY TYPE, 2024 (% SHARE)
  • FIGURE 23 ASIA PACIFIC: PHARMACEUTICAL INTERMEDIATE CDMO MARKETSHARE, BY FREQUENCY, 2024 (% SHARE)
  • FIGURE 24 ASIA PACIFIC: PHARMACEUTICAL INTERMEDIATE CDMO MARKETSHARE, BY APPLICATION, 2024 (% SHARE)
  • FIGURE 25 SOUTH AMERICA MARKET: SWOT ANALYSIS
  • FIGURE 26 SOUTH AMERICA: PHARMACEUTICAL INTERMEDIATE CDMO MARKETSHARE, BY COUNTRY, 2024 (% SHARE)
  • FIGURE 27 SOUTH AMERICA: PHARMACEUTICAL INTERMEDIATE CDMO MARKETSHARE, BY TYPE, 2024 (% SHARE)
  • FIGURE 28 SOUTH AMERICA: PHARMACEUTICAL INTERMEDIATE CDMO MARKETSHARE, BY FREQUENCY, 2024 (% SHARE)
  • FIGURE 29 SOUTH AMERICA: PHARMACEUTICAL INTERMEDIATE CDMO MARKETSHARE, BY APPLICATION, 2024 (% SHARE)
  • FIGURE 30 MIDDEL EAST AND AFRICA: SWOT ANALYSIS
  • FIGURE 31 MIDDEL EAST AND AFRICA: PHARMACEUTICAL INTERMEDIATE CDMO MARKETSHARE, BY COUNTRY, 2024 (% SHARE)
  • FIGURE 32 MIDDLE EAST & AFRICA: PHARMACEUTICAL INTERMEDIATE CDMO MARKETSHARE, BY COUNTRY, 2024 (% SHARE)
  • FIGURE 33 MIDDLE EAST & AFRICA: PHARMACEUTICAL INTERMEDIATE CDMO MARKETSHARE, BY TYPE, 2024 (% SHARE)
  • FIGURE 34 MIDDLE EAST & AFRICA: PHARMACEUTICAL INTERMEDIATE CDMO MARKETSHARE, BY FREQUENCY, 2024 (% SHARE)
  • FIGURE 35 MIDDLE EAST & AFRICA: PHARMACEUTICAL INTERMEDIATE CDMO MARKETSHARE, BY APPLICATION, 2024 (% SHARE)
  • FIGURE 36 GLOBAL PHARMACEUTICAL INTERMEDIATE CDMO MARKET: COMPETITIVE ANALSIS, 2024
  • FIGURE 37 COMPETITOR DASHBOARD: GLOBAL PHARMACEUTICAL INTERMEDIATE CDMO MARKET
  • FIGURE 38 RAGHAVA LIFE SCIENCES PVT LTD: SWOT ANALYSIS
  • FIGURE 39 ACTYLIS: SWOT ANALYSIS
  • FIGURE 40 CHIRACON GMBH: SWOT ANALYSIS
  • FIGURE 41 CODEXIS, INC.: SWOT ANALYSIS
  • FIGURE 42 ARKEMA S.A.: SWOT ANALYSIS
  • FIGURE 43 LONZA GROUP AG: SWOT ANALYSIS
  • FIGURE 44 THERMO FISHER SCIENTIFIC (PATHEON): SWOT ANALYSIS
  • FIGURE 45 CAMBREX CORPORATION: SWOT ANALYSIS
  • FIGURE 46 CATALENT, INC: SWOT ANALYSIS
  • FIGURE 47 ZHEJIANG JIUZHOU PHARMACEUTICAL CO LTD: SWOT ANALYSIS
目次

Global Pharmaceutical Intermediate CDMO Market Research Report by Application (Oncology, Cardiovascular Diseases, CNS & Neurological Disorders, Infectious Diseases), by Type of Intermediate [Active Pharmaceutical Ingredients (APIs), Excipients and Additives, Biologics Intermediates, Nucleotide Intermediates], by Drug Type (Generic Drugs, Branded Drugs), and by Region (North America, Europe, South America, Middle East and Africa, and Asia Pacific) Forecast Analysis till 2035

Industry Overview

In 2024, global pharmaceutical intermediate CDMO market was valued at USD 161,798.9 million. It is projected to increase at a compound annual growth rate (CAGR) of 7.4% from 2024 to 2035, reaching USD 346,744.3 million.

The global market for Pharmaceutical Intermediate CDMOs is expanding rapidly due to various contributing factors. Outsourcing by pharmaceutical firms is on the rise as they aim to enhance efficiency and reduce operational burdens. The increasing need for generic drugs and biosimilars, especially in low- and middle-income countries, is a major growth driver. Additionally, advancements in intermediate synthesis technologies and the complex nature of new drug formulations are pushing companies toward specialized CDMO support. The growth of healthcare infrastructure in emerging economies is also enhancing the market landscape.

On the flip side, stringent regulatory compliance requirements and lengthy approval timelines often hamper progress. High capital and operational expenses, intellectual property-related risks, and ongoing supply chain disruptions present notable barriers. A shortage of expertise in advanced chemistry remains another challenge. Despite these issues, the market holds promising opportunities through strategic alliances with biotechnology companies and the increasing demand for tailored, patient-specific medicine solutions.

Industry Segmentations

In terms of application types, the global market is divided into oncology, cardiovascular diseases, CNS and neurological disorders, and infectious disease.

Based on the drug type, global pharmaceutical intermediate CDMO market comprises generic drugs, branded drug.

Global Pharmaceutical intermediate CDMO market has been categorized by type of intermediate, includes active pharmaceutical ingredients (APIS), biologics intermediates, excipients and additives, nucleotide intermediates.

Regionally, global pharmaceutical intermediate CDMO market divided into North America, Europe, South America, Middle East and Africa, and Asia Pacific.

Regional Analysis

The North American market for pharmaceutical intermediate CDMOs is the largest and most sophisticated, with the U.S. leading due to high-tech infrastructure, heavy R&D investments, and FDA-enforced quality regulations. Canada's rising biopharmaceutical industry further supports regional strength.

Europe caters to both domestic powerhouses and global players, emphasizing regulatory compliance, innovation in complex syntheses, and sustainable production practices aligned with circular economy principles.

Asia Pacific, spearheaded by China and India, is witnessing the fastest growth. Cost-effective manufacturing, large-scale facilities, and integrated supply chains enable competitive production of intermediates.

Latin America, while facing diverse regulatory frameworks across countries, is working toward unified standards through regional cooperation. Competitive labor costs and proximity to the U.S. are advantageous, though growth is somewhat hindered by infrastructure constraints.

In the Middle East and Africa, CDMOs largely serve local and neighboring markets by producing intermediates for generic medicines and essential drugs. The region's favorable location between Asia and Europe positions it as a potential hub in pharmaceutical logistics and intermediate supply. As global supply chains evolve, MEA's role may become more pronounced in bridging manufacturing efforts across continents.

Key Players

Thermo Fisher Scientific, Raghava Life Sciences Pvt LTD., Cambrex Corporation, Actylis, Chiracon GmbH, Codexis, Inc., Arkema S.A., Lonza Group AG, Catalent, Inc., Zhejiang Jiuzhou Pharmaceutical Co Ltd are the key competitors of the global pharmaceutical intermediate CDMO market.

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

  • 1.1 MARKET OVERVIEW:
  • 1.2 MARKET SEGMENTATION
  • 1.3 COMPETITIVE LANDSCAPE
  • 1.4 FUTURE OUTLOOK

2 MARKET INTRODUCTION

  • 2.1 DEFINITION
  • 2.2 SCOPE OF THE STUDY
  • 2.3 RESEARCH OBJECTIVE
  • 2.4 MARKET STRUCTURE

3 RESEARCH METHODOLOGY

  • 3.1 OVERVIEW
  • 3.2 DATA FLOW
    • 3.2.1 Data Mining Process
  • 3.3 PURCHASED DATABASE:
  • 3.4 SECONDARY SOURCES:
    • 3.4.1 Secondary Research Data Flow:
  • 3.5 PRIMARY RESEARCH:
    • 3.5.1 Primary Research DATA FLOW:
    • 3.5.2 Primary Research: Number of Interviews conducted
    • 3.5.3 Primary Research: Regional Coverage
  • 3.6 APPROACHES FOR MARKET END USER ESTIMATION:
    • 3.6.1 Revenue Analysis Approach
    • 3.6.2 Data forecasting
    • 3.6.3 Data Forecasting Technique
  • 3.7 DATA MODELING
    • 3.7.1 microeconomic factor analysis:
    • 3.7.2 Data modeling:
  • 3.8 TEAMS AND ANALYST CONTRIBUTION

4 MARKET DYNAMICS

  • 4.1 INTRODUCTION
  • 4.2 DRIVERS
    • 4.2.1 Increasing Outsourcing by Pharmaceutical Companies
    • 4.2.2 Rising Demand for Generic Drugs and Biosimilars
    • 4.2.3 Technological Advancements in Intermediate Synthesis
    • 4.2.4 Growing Complexity of Drug Molecules
    • 4.2.5 Expansion in Emerging Markets
  • 4.3 RESTRAINTS
    • 4.3.1 Stringent Regulatory Compliance and Complex Approval Processes
    • 4.3.2 High Operational and Capital Expenditure Costs
    • 4.3.3 Property (IP) Risks and Confidentiality Concerns
    • 4.3.4 Supply Chain Disruptions and Raw Material Shortages
    • 4.3.5 Limited Expertise in Advanced Technologies and Niche Chemistry
  • 4.4 OPPORTUNITY
    • 4.4.1 Strategic Partnerships with Biotech Firms
    • 4.4.2 Focus on Personalized Medicine Solutions
  • 4.5 IMPACT ANALYSIS OF COVID - 19

5 MARKET FACTOR ANALYSIS

  • 5.1 SUPPLY CHAIN ANALYSIS
    • 5.1.1 Raw Material Sourcing & Procurement
    • 5.1.2 Research, Development, & Process Optimization
    • 5.1.3 Manufacturing & Quality Control
    • 5.1.4 Packaging, Storage, & Logistics & Distribution & Customer Delivery
  • 5.2 PORTER'S FIVE FORCES MODEL
    • 5.2.1 Threat of New Entrants (Low to Moderate)
    • 5.2.2 Bargaining Power of Suppliers (Moderate)
    • 5.2.3 Threat of Substitutes (Low to Moderate)
    • 5.2.4 Bargaining Power of Buyers (High)
    • 5.2.5 Intensity of Rivalry (High)

6 GLOBAL PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE

  • 6.1 INTRODUCTION
  • 6.2 ACTIVE PHARMACEUTICAL INGREDIENTS (APIS)
  • 6.3 EXCIPIENTS & ADDITIVES

7 GLOBAL PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE

  • 7.1 INTRODUCTION
  • 7.2 GENERIC DRUGS
  • 7.3 BRANDED DRUGS

8 GLOBAL PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION

  • 8.1 INTRODUCTION
  • 8.2 ONCOLOGY
  • 8.3 CARDIOVASCULAR DISEASES
  • 8.4 CNS & NEUROLOGICAL DISORDERS
  • 8.5 INFECTIOUS DISEASES
  • 8.6 OTHERS

9 GLOBAL PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY REGION

  • 9.1 GLOBAL
  • 9.2 NORTH AMERICA
    • 9.2.1 USA
    • 9.2.2 CANADA
  • 9.3 EUROPE
    • 9.3.1 united kingdom
    • 9.3.2 germany
    • 9.3.3 france
    • 9.3.4 italy
    • 9.3.5 spain
    • 9.3.6 RUSSIA
    • 9.3.7 rest of europe
  • 9.4 ASIA PACIFIC
    • 9.4.1 china
    • 9.4.2 South Korea
    • 9.4.3 indiA
    • 9.4.4 Japan
    • 9.4.5 indonesia
    • 9.4.6 malaysia
    • 9.4.7 thailand
    • 9.4.8 rest of asia pacific
  • 9.5 SOUTH AMERICA
    • 9.5.1 Mexico
    • 9.5.2 Brazil
    • 9.5.3 argentina
    • 9.5.4 rest of south america
  • 9.6 MIDDEL EAST AND AFRICA
    • 9.6.1 gcc countries
    • 9.6.2 south africa
    • 9.6.3 rest of middle east & africa

10 COMPETITIVE LANDSCAPE

  • 10.1 INTRODUCTION
  • 10.2 MARKET SHARE ANALYSIS, 2024SS
  • 10.3 COMPETITOR DASHBOARD

11 COMPANY PROFILES

  • 11.1 RAGHAVA LIFE SCIENCES PVT LTD
    • 11.1.1 COMPANY OVERVIEW
    • 11.1.2 Key Development
    • 11.1.3 SWOT ANALYSIS
    • 11.1.4 Key Strategy
  • 11.2 ACTYLIS
    • 11.2.1 COMPANY OVERVIEW
    • 11.2.2 PRODUCT OFFERED
    • 11.2.3 Key Development
    • 11.2.4 SWOT ANALYSIS
    • 11.2.5 Key Strategy
  • 11.3 CHIRACON GMBH
    • 11.3.1 COMPANY OVERVIEW
    • 11.3.2 PRODUCT OFFERED
    • 11.3.3 SWOT ANALYSIS
    • 11.3.4 Key Strategy
  • 11.4 CODEXIS, INC.
    • 11.4.1 COMPANY OVERVIEW
    • 11.4.2 PRODUCT OFFERED
    • 11.4.3 Key Development
    • 11.4.4 SWOT ANALYSIS
    • 11.4.5 financial analysis
    • 11.4.6 Key Strategy
  • 11.5 ARKEMA S.A.
    • 11.5.1 COMPANY OVERVIEW
    • 11.5.2 PRODUCT OFFERED
    • 11.5.3 SWOT ANALYSIS
    • 11.5.4 financial analysis
    • 11.5.5 Key Strategy
  • 11.6 LONZA GROUP AG
    • 11.6.1 COMPANY OVERVIEW
    • 11.6.2 PRODUCT OFFERED
    • 11.6.3 Key Development
    • 11.6.4 SWOT ANALYSIS
    • 11.6.5 financial analysis
    • 11.6.6 Key Strategy
  • 11.7 THERMO FISHER SCIENTIFIC (PATHEON)
    • 11.7.1 COMPANY OVERVIEW
    • 11.7.2 PRODUCT OFFERED
    • 11.7.3 Key Development
    • 11.7.4 SWOT ANALYSIS
    • 11.7.5 financial analysis
    • 11.7.6 Key Strategy
  • 11.8 CAMBREX CORPORATION
    • 11.8.1 COMPANY OVERVIEW
    • 11.8.2 PRODUCT OFFERED
    • 11.8.3 Key Development
    • 11.8.4 SWOT ANALYSIS
    • 11.8.5 Key Strategy
  • 11.9 CATALENT, INC.
    • 11.9.1 COMPANY OVERVIEW
    • 11.9.2 PRODUCT OFFERED
    • 11.9.3 Key Development
    • 11.9.4 SWOT ANALYSIS
    • 11.9.5 financial analysis
    • 11.9.6 Key Strategy
  • 11.10 ZHEJIANG JIUZHOU PHARMACEUTICAL CO LTD
    • 11.10.1 COMPANY OVERVIEW
    • 11.10.2 PRODUCT OFFERED
    • 11.10.3 Key Development
    • 11.10.4 SWOT ANALYSIS
    • 11.10.5 financial analysis
    • 11.10.6 Key Strategy